Contact

DMPK

DMPK studies are crucial in drug discovery and development bring integral in predicting human exposure and clinical efficacy. Concentrating research efforts on identifying DMPK-related failures early in the process leads to significant savings in both cost and time for research programs.

Expert DMPK Services

Sygnature Discovery’s DMPK services for drug discovery span across three sites Alderley Park, Nottingham and Montreal, combining the expertise of our senior scientists gained in big pharma, biotech, CROs and academia. With proven experience in DMPK our scientists offer detailed DMPK data interpretation to guide decision-making in drug programs.

By leveraging in vitro DMPK services, in vivo DMPK services, bioanalysis, biotransformation, modelling and simulation, and formulation support, we foster strong client collaboration and design custom studies that meet specific project needs. This bespoke approach improves data relevance, thereby allowing data informed decisions to improve project success rates. 

 

Tiered Approaches to Compound Progression

Working closely within Sygnature’s global scientific network – the flexibility we have in what DMPK tools and when we employ them allows DMPK to support each individual medicinal chemistry program to identify potential issues and address them appropriately. We collaborate with customers to understand:

  • The target product profile
  • Essential drug properties required to meet the medical need
  • Critical success factors defined by the customer

Our DMPK Offerings

  • Integrated drug discovery solutions, ensuring DMPK plays a key role throughout research
  • Preclinical DMPK studies, supporting early-stage compound assessment
  • Standalone Fee-for-Service (FFS) contracts (in vitro & in vivo) with continued Client Services support
  • DMPK consultancy, offering expert interpretation for strategic guidance

 

State-of-the-Art Analytical Equipment for DMPK Studies

Our facilities feature a wide range of advanced analytical instruments from several leading vendors to support our DMPK studies. These include state-of-the-art mass spectrometry platforms and complementary technologies that deliver the sensitivity, accuracy and reliability for high-quality data. This diverse instrumentation allows us to tailor workflows to suit the specific requirements of each project. 

DMPK Services

DMPK Consultancy

Sygnature’s DMPK consultants bring decades of expertise to help design efficient drug metabolism strategies. We collaborate across disciplines to align ADME profiling, PK and modelling with your project goals, ensuring the right studies are done at the right time for better candidate progression.

DISCOVER

Modelling and Simulation

Our modelling and simulation services integrate experimental data with predictive software to guide dose selection, human PK projections and DDI risk assessment. Sygnature’s mechanistic and empirical modelling capabilities enhance translational insight, reducing risk and informing clinical strategy.

DISCOVER

In Vitro ADME & Physicochemical Profiling

Sygnature Discovery offers comprehensive in vitro ADME and physiochemical profiling to guide early compound optimization. Our expert team employs assays to assess permeability, solubility, metabolic stability and more, supporting informed decision making in drug design and lead candidate selection.

DISCOVER

In Vivo Pharmacokinetics & Bioanalysis

Sygnature Discovery provides in vivo pharmacokinetic (PK) studies and robust bioanalytical services across multiple species. Our integrated approach supports rapid compound assessment and optimization, with regulatory-aligned LC-MS/MS methods delivering precise quantification to accelerate preclinical decision-making.

DISCOVER

Metabolite Identification & Method Development

We deliver high-resolution mass spectrometry-based metabolite-identification to characterize biotransformation pathways. Our tailored method development ensures accurate bioanalytical quantification of parent drugs and metabolites, supporting safety and efficacy evaluations across discovery and development stages.

DISCOVER

Latest News

View All

Leading UK Drug Discovery CROs Unite as…

Sygnature Discovery Announces Expansion at Alderley Park

Understanding & Predicting Brain Penetration for CNS-targeted…